Time to onset and duration of botulinum toxin efficacy in movement disorders.
Botulinum toxin
Duration
Efficacy
Movement disorders
Sialorrhea
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
10
11
2021
accepted:
23
01
2022
revised:
21
01
2022
pubmed:
4
2
2022
medline:
25
6
2022
entrez:
3
2
2022
Statut:
ppublish
Résumé
Botulinum toxin (BoNT) is a valuable treatment in movement disorders; however, time to onset and duration of efficacy may widely differ among patients. We aimed to clarify the impact of main demographic and clinical features on time to onset and duration of BoNT efficacy. We analyzed time-to-onset and duration of BoNT efficacy in 186 consecutive patients treated with BoNT for blepharospasm, cervical dystonia, facial hemispasm, oromandibular dystonia, limb dystonia, and sialorrhea due to Parkinsonism. The following factors were considered as potential efficacy predictors: doses and types of toxin, sex, age, years of treatment, and clinical condition. Kruskall-Wallis, Spearman correlation, and multivariate linear regression were used for statistical analysis. The average time to onset was 6.7 ± 5 days and duration of BONT efficacy 78.5 ± 28.4 days. Both time to onset and duration of efficacy were correlated with BoNT doses (p: 0.007 and p: 0.02). The multiple regression analysis showed that sex, age, years of BoNT treatment, doses, type of toxin, and clinical condition significantly predicted time to onset (F(11, 171) = 2.146, p: 0.020) with age being the strongest predictor (p: 0.004). The same model explained 20.1% of the variance of duration of BoNT efficacy, showing a significant prediction of the outcome (F(11, 164) = 3.754, p < 0.001), with doses (p < 0.001), type of toxin (p: 0.017), and clinical condition (p < 0.001) being the strongest predictors. Our findings suggest that age, type of toxin, clinical condition and especially doses may account for the variability of BoNT efficacy in terms of time to onset and duration.
Sections du résumé
BACKGROUND
BACKGROUND
Botulinum toxin (BoNT) is a valuable treatment in movement disorders; however, time to onset and duration of efficacy may widely differ among patients. We aimed to clarify the impact of main demographic and clinical features on time to onset and duration of BoNT efficacy.
METHODS
METHODS
We analyzed time-to-onset and duration of BoNT efficacy in 186 consecutive patients treated with BoNT for blepharospasm, cervical dystonia, facial hemispasm, oromandibular dystonia, limb dystonia, and sialorrhea due to Parkinsonism. The following factors were considered as potential efficacy predictors: doses and types of toxin, sex, age, years of treatment, and clinical condition. Kruskall-Wallis, Spearman correlation, and multivariate linear regression were used for statistical analysis.
RESULTS
RESULTS
The average time to onset was 6.7 ± 5 days and duration of BONT efficacy 78.5 ± 28.4 days. Both time to onset and duration of efficacy were correlated with BoNT doses (p: 0.007 and p: 0.02). The multiple regression analysis showed that sex, age, years of BoNT treatment, doses, type of toxin, and clinical condition significantly predicted time to onset (F(11, 171) = 2.146, p: 0.020) with age being the strongest predictor (p: 0.004). The same model explained 20.1% of the variance of duration of BoNT efficacy, showing a significant prediction of the outcome (F(11, 164) = 3.754, p < 0.001), with doses (p < 0.001), type of toxin (p: 0.017), and clinical condition (p < 0.001) being the strongest predictors.
CONCLUSION
CONCLUSIONS
Our findings suggest that age, type of toxin, clinical condition and especially doses may account for the variability of BoNT efficacy in terms of time to onset and duration.
Identifiants
pubmed: 35113259
doi: 10.1007/s00415-022-10995-2
pii: 10.1007/s00415-022-10995-2
pmc: PMC9217780
doi:
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3706-3712Informations de copyright
© 2022. The Author(s).
Références
Jankovic J (2017) Botulinum toxin: state of the art. Mov Disord 32(8):1131–1138. https://doi.org/10.1002/mds.27072
doi: 10.1002/mds.27072
pubmed: 28639368
Wortzman MS, Pickett A (2009) The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthet Surg J 29(6 Suppl):S34-42. https://doi.org/10.1016/j.asj.2009.09.014
doi: 10.1016/j.asj.2009.09.014
pubmed: 19945003
Samizadeh S, De Boulle K (2018) Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol 30(11):273–287. https://doi.org/10.2147/CCID.S156851
doi: 10.2147/CCID.S156851
Rappl T, Parvizi D, Friedl H, Wiedner M, May S, Kranzelbinder B, Wurzer P, Hellbom B (2013) Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol 6:211–219. https://doi.org/10.2147/CCID.S41537
doi: 10.2147/CCID.S41537
pubmed: 24098087
pmcid: 3789632
Eleopra R, Rinaldo S, Montecucco C, Rossetto O, Devigili G (2020) Clinical duration of action of different botulinum toxin types in humans. Toxicon 179:84–91. https://doi.org/10.1016/j.toxicon.2020.02.020
doi: 10.1016/j.toxicon.2020.02.020
pubmed: 32184153
Bonaparte JP, Ellis D, Quinn JG, Ansari MT, Rabski J, Kilty SJ (2013) A comparative assessment of three formulations of botulinum toxin A for facial rhytides: a systematic review and meta-analyses. Syst Rev 2:40. https://doi.org/10.1186/2046-4053-2-40
doi: 10.1186/2046-4053-2-40
pubmed: 23763852
pmcid: 3686697
Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H (1998) A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64(1):6–12. https://doi.org/10.1136/jnnp.64.1.6
doi: 10.1136/jnnp.64.1.6
pubmed: 9436720
pmcid: 2169916
Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72(4):459–462. https://doi.org/10.1136/jnnp.72.4.459
doi: 10.1136/jnnp.72.4.459
pubmed: 11909903
pmcid: 1737843
Anandan C, Jankovic J (2021) Botulinum toxin in movement disorders: an update. Toxins (Basel) 13(1):42. https://doi.org/10.3390/toxins13010042
doi: 10.3390/toxins13010042
pmcid: 7827923
Sampaio C, Ferreira JJ, Pinto AA, Crespo M, Ferro JM, Castro-Caldas A (1997) Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 11(1):3–7. https://doi.org/10.1177/026921559701100102
doi: 10.1177/026921559701100102
pubmed: 9065354
Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A (2009) Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol 16(3):392–398. https://doi.org/10.1111/j.1468-1331.2008.02507.x
doi: 10.1111/j.1468-1331.2008.02507.x
pubmed: 19364366
Kollewe K, Mohammadi B, Köhler S, Pickenbrock H, Dengler R, Dressler D (2015) Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®. J Neural Transm (Vienna) 122(3):427–431. https://doi.org/10.1007/s00702-014-1278-z
doi: 10.1007/s00702-014-1278-z
Tuğan Yıldız B, Tuncel Berktaş D (2021) Experiences on the administration of botulinum toxin in movement disorders. J Transl Int Med 9(1):52–56. https://doi.org/10.2478/jtim-2021-0003
doi: 10.2478/jtim-2021-0003
pubmed: 33850802
pmcid: 8016350
Siparsky PN, Kirkendall DT, Garrett WE Jr (2014) Muscle changes in aging: understanding sarcopenia. Sports Health 6(1):36–40. https://doi.org/10.1177/1941738113502296
doi: 10.1177/1941738113502296
pubmed: 24427440
pmcid: 3874224
Nagler RM (2004) Salivary glands and the aging process: mechanistic aspects, health-status and medicinal-efficacy monitoring. Biogerontology 5(4):223–233. https://doi.org/10.1023/B:BGEN.0000038023.36727.50
doi: 10.1023/B:BGEN.0000038023.36727.50
pubmed: 15314272
Dolly JO, Aoki KR (2006) The structure and mode of action of different botulinum toxins. Eur J Neurol 13(Suppl 4):1–9. https://doi.org/10.1111/j.1468-1331.2006.01648.x
doi: 10.1111/j.1468-1331.2006.01648.x
pubmed: 17112344
Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114. https://doi.org/10.1016/j.toxicon.2012.12.004
doi: 10.1016/j.toxicon.2012.12.004
pubmed: 23380701
Bihari K (2005) Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 21(3):433–438. https://doi.org/10.1185/030079905X36396
doi: 10.1185/030079905X36396
pubmed: 15811212
Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Künig G (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 64(1):13–17. https://doi.org/10.1136/jnnp.64.1.13
doi: 10.1136/jnnp.64.1.13
pubmed: 9436721
pmcid: 2169893
Poewe W, Burbaud P, Castelnovo G, Jost WH, Ceballos-Baumann AO, Banach M, Potulska-Chromik A, Ferreira JJ, Bihari K, Ehler E, Bares M, Dzyak LA, Belova AN, Pham E, Liu WJ, Picaut P (2016) Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial. Mov Disord 31(11):1649–1657. https://doi.org/10.1002/mds.26760 (Epub 2016 Sep 21)
doi: 10.1002/mds.26760
pubmed: 27653448
Li YJ, Huang Y, Ding Q, Gu ZH, Pan XL (2015) Evaluation of concentrations of botulinum toxin A for the treatment of hemifacial spasm: a randomized double-blind crossover trial. Genet Mol Res 14(1):1136–1144. https://doi.org/10.4238/2015.February.6.17
doi: 10.4238/2015.February.6.17
pubmed: 25730053
Flynn TC (2010) Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol 11(3):183–199. https://doi.org/10.2165/11530110-000000000-00000
doi: 10.2165/11530110-000000000-00000
pubmed: 20369902